MX2021010115A - Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. - Google Patents
Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.Info
- Publication number
- MX2021010115A MX2021010115A MX2021010115A MX2021010115A MX2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- myeloid leukemia
- acute myeloid
- pharmaceutical composition
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190021228 | 2019-02-22 | ||
| KR1020200021502A KR20200102949A (ko) | 2019-02-22 | 2020-02-21 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| PCT/KR2020/002536 WO2020171646A1 (ko) | 2019-02-22 | 2020-02-21 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010115A true MX2021010115A (es) | 2021-09-21 |
Family
ID=72144358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010115A MX2021010115A (es) | 2019-02-22 | 2020-02-21 | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12433867B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7577672B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016522A2 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2021002217A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021010115A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20212153A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021551985A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020171646A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EP3991733A4 (en) * | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| EP4525873A1 (en) | 2022-05-17 | 2025-03-26 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| KR20090087094A (ko) | 2006-11-28 | 2009-08-14 | 노파르티스 아게 | Iap 억제제 및 flt3 억제제의 조합물 |
| JPWO2008111441A1 (ja) | 2007-03-05 | 2010-06-24 | 協和発酵キリン株式会社 | 医薬組成物 |
| CA2702126A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| TW201022262A (en) | 2008-10-29 | 2010-06-16 | Astrazeneca Ab | Novel compounds 515 |
| CN102438588B (zh) | 2009-03-23 | 2015-04-01 | 埃姆比特生物科学公司 | 使用联合治疗法治疗疾病的方法 |
| US8435980B2 (en) | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
| ES2622138T3 (es) | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| EP2832734A4 (en) | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| WO2014155300A2 (en) | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| CA2949793C (en) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN113121575A (zh) | 2014-08-25 | 2021-07-16 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| JP6564449B2 (ja) | 2015-02-20 | 2019-08-21 | 第一三共株式会社 | がんの併用治療法 |
| WO2016155655A1 (zh) | 2015-04-03 | 2016-10-06 | 上海瑛派药业有限公司 | Parp抑制剂固体药物剂型及其应用 |
| KR101799781B1 (ko) | 2015-07-23 | 2017-11-22 | 재단법인 강릉과학산업진흥원 | 소뼈 추출분말의 제조방법 |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN107531725B (zh) | 2015-08-13 | 2021-03-19 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
| CA2998042C (en) | 2015-09-14 | 2022-07-05 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
| BR112018009463A8 (pt) | 2015-11-11 | 2019-02-26 | Celator Pharmaceuticals Inc | ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia |
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| EP3436014A4 (en) * | 2016-03-29 | 2019-11-27 | Astellas Pharma Inc. | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
| PL3541387T3 (pl) | 2016-11-15 | 2021-10-25 | Novartis Ag | Dawka i schemat dla inhibitorów interakcji hdm2-p53 |
| MA47233A (fr) | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| PE20191108A1 (es) | 2017-01-17 | 2019-08-26 | Astrazeneca Ab | Inhibidores selectivos de jak1 |
| KR102175710B1 (ko) | 2017-01-23 | 2020-11-06 | 주식회사 엘지화학 | 폴리아릴렌 설파이드 수지 조성물 |
| TWI810172B (zh) | 2017-01-26 | 2023-08-01 | 南韓商韓美藥品股份有限公司 | 嘧啶化合物及包括其的藥學組成物 |
| KR20190128646A (ko) | 2017-02-21 | 2019-11-18 | 압토스 바이오사이언시스 인코포레이티드 | 혈액 종양 환자들의 치료 방법 |
| WO2019025484A1 (en) | 2017-08-01 | 2019-02-07 | Julius-Maximilians-Universität Würzburg | USE OF CAR-MODIFIED T LYMPHOCYTES FOR FLT3 AND FLT3 INHIBITORS FOR TREATING ACUTE MYELOID LEUKEMIA |
| CA3080197C (en) | 2017-10-27 | 2023-12-19 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102297587B1 (ko) | 2018-08-07 | 2021-09-06 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN113166110B (zh) | 2018-12-12 | 2023-08-11 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| EP3928780A4 (en) | 2019-02-22 | 2022-12-07 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| WO2020171649A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| WO2021066443A1 (ko) | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| WO2021159993A1 (en) | 2020-02-14 | 2021-08-19 | Pharmablock Sciences (Nanjing) , Inc. | Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof |
| CN116583284A (zh) | 2020-11-05 | 2023-08-11 | 韩美药品株式会社 | 用于治疗髓性白血病的包括flt3抑制剂的药物组合物 |
| KR20230056331A (ko) | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| AU2023372170A1 (en) | 2022-11-04 | 2025-04-24 | Hanmi Pharm. Co., Ltd. | Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof |
| CN120857931A (zh) | 2022-12-10 | 2025-10-28 | 艾普托斯生物科学公司 | 用于治疗患有血液学恶性病的患者的方法 |
| EP4719355A1 (en) | 2023-05-31 | 2026-04-08 | Hanmi Pharm. Co., Ltd. | Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same |
-
2020
- 2020-02-21 BR BR112021016522-3A patent/BR112021016522A2/pt not_active IP Right Cessation
- 2020-02-21 MX MX2021010115A patent/MX2021010115A/es unknown
- 2020-02-21 PE PE2021001382A patent/PE20212153A1/es unknown
- 2020-02-21 JP JP2021547541A patent/JP7577672B2/ja active Active
- 2020-02-21 US US17/432,699 patent/US12433867B2/en active Active
- 2020-02-21 WO PCT/KR2020/002536 patent/WO2020171646A1/ko not_active Ceased
- 2020-02-21 PH PH1/2021/551985A patent/PH12021551985A1/en unknown
-
2021
- 2021-08-19 CL CL2021002217A patent/CL2021002217A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002217A1 (es) | 2022-04-29 |
| JP2022521380A (ja) | 2022-04-07 |
| BR112021016522A2 (pt) | 2021-10-26 |
| JP7577672B2 (ja) | 2024-11-05 |
| WO2020171646A1 (ko) | 2020-08-27 |
| US20220110913A1 (en) | 2022-04-14 |
| US12433867B2 (en) | 2025-10-07 |
| PH12021551985A1 (en) | 2022-08-22 |
| PE20212153A1 (es) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551985A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| MX2021015724A (es) | Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| JOP20220130A1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| MX385265B (es) | Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas | |
| MY208662A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
| EA202191984A1 (ru) | Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2025003515A (es) | Moduladores de akt1 | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2025005474A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| ZA202307855B (en) | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome | |
| PH12020551772A1 (en) | Oxo-substituted compound |